Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models

References

• HIV/AIDS http://www.who.int/mediacentre/factsheets/fs360/en/ Accessed: August 6, 2015.
   Google Scholar
• UNAIDS fact sheet http://www.unaids.org/en/resources/campaigns/globalreport2013/factsheet Accessed: August 6, 2015.
   Google Scholar
• Shankarappa R, Margolick JB, Gange SJ, et al. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol. 1999;73(12):10489–10502.
   PubMed Web of Science ®Google Scholar
• Hemelaar J. The origin and diversity of the HIV-1 pandemic. Trends Mol Med. 2012;18(3):182–192.
   PubMed Web of Science ®Google Scholar
• Korber B, Gaschen B, Yusim K, et al. Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull. 2001;58:19–42.
   PubMed Web of Science ®Google Scholar
• Excler JL, Robb ML, Kim JH. HIV-1 vaccines: challenges and new perspectives. Hum Vaccin Immunother. 2014;10(6):1734–1746.
   PubMed Web of Science ®Google Scholar
• Phanuphak N, Lo YR, Shao Y, et al. HIV epidemic in Asia: implications for HIV vaccine and other prevention trials. AIDS Res Hum Retroviruses. 2015;31(11):1060–1076.
   PubMed Web of Science ®Google Scholar
• Excler JL, Ake J, Robb ML, et al. Nonneutralizing functional antibodies: a new “old” paradigm for HIV vaccines. Clin Vaccine Immunol. 2014;21(8):1023–1036.
   PubMed Web of Science ®Google Scholar
• Su B, Moog C. Which antibody functions are important for an HIV Vaccine? Front Immunol. 2014;5:289.
   PubMed Web of Science ®Google Scholar
• Burton DR, Ahmed R, Barouch DH, et al. A blueprint for HIV vaccine discovery. Cell Host Microbe. 2012;12(4):396–407.
   PubMed Web of Science ®Google Scholar
• Petrovas C, Yamamoto T, Gerner MY, et al. CD4 T follicular helper cell dynamics during SIV infection. J Clin Invest. 2012;122(9):3281–3294.
   PubMed Web of Science ®Google Scholar
• Flynn NM, Forthal DN, Harro CD, et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis. 2005;191(5):654–665.
   PubMed Web of Science ®Google Scholar
• Gilbert PB, Peterson ML, Follmann D, et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis. 2005;191(5):666–677.
   PubMed Web of Science ®Google Scholar
• Pitisuttithum P, Gilbert P, Gurwith M, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis. 2006;194(12):1661–1671.
   PubMed Web of Science ®Google Scholar
• Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008;372(9653):1881–1893.
   PubMed Web of Science ®Google Scholar
• McElrath MJ, De Rosa SC, Moodie Z, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet. 2008;372(9653):1894–1905.
   PubMed Web of Science ®Google Scholar
• Hammer SM, Sobieszczyk ME, Janes H, et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med. 2013;369(22):2083–2092.
   PubMed Web of Science ®Google Scholar
• Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361(23):2209–2220.
   PubMed Web of Science ®Google Scholar
• Vaccari M, Poonam P, Franchini G. Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV. Expert Rev Vaccines. 2010;9(9):997–1005.
   PubMed Web of Science ®Google Scholar
• Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012;366(14):1275–1286.
   PubMed Web of Science ®Google Scholar
• Hanke T, Blanchard TJ, Schneider J, et al. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine. 1998;16(5):439–445.
   PubMed Web of Science ®Google Scholar
• Gherardi MM, Perez-Jimenez E, Najera JL, et al. Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule. J Immunology. 2004;172(10):6209–6220.
   PubMed Web of Science ®Google Scholar
• Gomez CE, Abaitua F, Rodriguez D, et al. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma. Virus Res. 2004;105(1):11–22.
   PubMed Web of Science ®Google Scholar
• Abaitua F, Rodriguez JR, Garzon A, et al. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma. Virus Res. 2006;116(1–2):11–20.
   PubMed Web of Science ®Google Scholar
• Liu J HM, McDonnel M, Amara RR, et al. Dose-response studies for the elicitation of CD8 T cells by a DNA vaccine, used alone or as the prime for a modified vaccinia Ankara boost. Vaccine. 2007;25(15):2951–2958.
   PubMed Web of Science ®Google Scholar
• Brave A, Boberg A, Gudmundsdotter L, et al. A new multi-clade DNA prime/recombinant MVA boost vaccine induces broad and high levels of HIV-1-specific CD8(+) T-cell and humoral responses in mice. Mol Therapy: J Am Soc Gene Ther. 2007;15(9):1724–1733.
   PubMed Web of Science ®Google Scholar
• Belyakov IM, Ahlers JD, Nabel GJ, et al. Generation of functionally active HIV-1 specific CD8+ CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization. Virology. 2008;381(1):106–115.
   PubMed Web of Science ®Google Scholar
• Hallengard D, Applequist SE, Nystrom S, et al. Immunization with multiple vaccine modalities induce strong HIV-specific cellular and humoral immune responses. Viral Immunol. 2012;25(5):423–432.
   PubMed Web of Science ®Google Scholar
• Mothe B, Hu X, Llano A, et al. A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques. J Transl Med. 2015;13:60.
   PubMed Web of Science ®Google Scholar
• Fuller DH, Simpson L, Cole KS, et al. Gene gun-based nucleic acid immunization alone or in combination with recombinant vaccinia vectors suppresses virus burden in rhesus macaques challenged with a heterologous SIV. Immunol Cell Biol. 1997;75(4):389–396.
   PubMed Web of Science ®Google Scholar
• Robinson HL, Montefiori DC, Johnson RP, et al. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat Med. 1999;5(5):526–534.
   PubMed Web of Science ®Google Scholar
• Allen TM, Vogel TU, Fuller DH, et al. Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J Immunology. 2000;164(9):4968–4978.
   PubMed Web of Science ®Google Scholar
• Amara RR, Villinger F, Altman JD, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science. 2001;292(5514):69–74.
   PubMed Web of Science ®Google Scholar
• Horton H, Vogel TU, Carter DK, et al. Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239. J Virol. 2002;76(14):7187–7202.
   PubMed Web of Science ®Google Scholar
• Manrique M, Kozlowski PA, Wang SW, et al. Nasal DNA-MVA SIV vaccination provides more significant protection from progression to AIDS than a similar intramuscular vaccination. Mucosal Immunol. 2009;2(6):536–550.
   PubMed Web of Science ®Google Scholar
• Cox JH, Ferrari MG, Earl P, et al. Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge. Vaccine. 2012;30(10):1830–1840.
   PubMed Web of Science ®Google Scholar
• Barouch DH, Liu J, Li H, et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature. 2012;482(7383):89–93.
   PubMed Web of Science ®Google Scholar
• Cebere I, Dorrell L, McShane H, et al. Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine. 2006;24(4):417–425.
   PubMed Web of Science ®Google Scholar
• Goonetilleke N, Moore S, Dally L, et al. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes. J Virol. 2006;80(10):4717–4728.
   PubMed Web of Science ®Google Scholar
• Hanke T, Goonetilleke N, McMichael AJ, et al. Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction. J Gen Virol. 2007;88(Pt 1):1–12.
   PubMed Web of Science ®Google Scholar
• Sandstrom E, Nilsson C, Hejdeman B, et al. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis. 2008;198(10):1482–1490.
   PubMed Web of Science ®Google Scholar
• Guimaraes-Walker A, Mackie N, McCormack S, et al. Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers. Vaccine. 2008;26(51):6671–6677.
   PubMed Web of Science ®Google Scholar
• Aboud S, Nilsson C, Karlen K, et al. Strong HIV-specific CD4+ and CD8+ T-lymphocyte proliferative responses in healthy individuals immunized with an HIV-1 DNA vaccine and boosted with recombinant modified vaccinia virus ankara expressing HIV-1 genes. Clin Vaccine Immunol. 2010;17(7):1124–1131.
   PubMed Web of Science ®Google Scholar
• Goepfert PA, Elizaga ML, Sato A, et al. Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis. 2011;203(5):610–619.
   PubMed Web of Science ®Google Scholar
• Nilsson C, Godoy-Ramirez K, Hejdeman B, et al. Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-boosted Swedish vaccinees. AIDS Res Hum Retroviruses. 2014;30(3):299–311.
   PubMed Web of Science ®Google Scholar
• Xiang ZQ, Spitalnik S, Tran M, et al. Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus. Virology. 1994;199(1):132–140.
   PubMed Web of Science ®Google Scholar
• Robinson HL, Hunt LA, Webster RG. Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA. Vaccine. 1993;11(9):957–960.
   PubMed Web of Science ®Google Scholar
• Ulmer JB, Donnelly JJ, Parker SE, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 1993;259(5102):1745–1749.
   PubMed Web of Science ®Google Scholar
• Roy MJ, Wu MS, Barr LJ, et al. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine. 2000;19(7–8):764–778.
   PubMed Web of Science ®Google Scholar
• MacGregor RR, Boyer JD, Ugen KE, et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis. 1998;178(1):92–100.
   PubMed Web of Science ®Google Scholar
• Graham BS, Koup RA, Roederer M, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis. 2006;194(12):1650–1660.
   PubMed Web of Science ®Google Scholar
• Saade F, Petrovsky N. Technologies for enhanced efficacy of DNA vaccines. Expert Rev Vaccines. 2012;11(2):189–209.
   PubMed Web of Science ®Google Scholar
• Flingai S, Czerwonko M, Goodman J, et al. Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants. Front Immunol. 2013;4:354.
   PubMed Web of Science ®Google Scholar
• Villarreal DO, Talbott KT, Choo DK, et al. Synthetic DNA vaccine strategies against persistent viral infections. Expert Rev Vaccines. 2013;12(5):537–554.
   PubMed Web of Science ®Google Scholar
• Low L, Mander A, McCann K, et al. DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer. Hum Gene Ther. 2009;20(11):1269–1278.
   PubMed Web of Science ®Google Scholar
• Vasan S, Hurley A, Schlesinger SJ, et al. In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PloS One. 2011;6(5):e19252.
   PubMed Web of Science ®Google Scholar
• Kutzler MA, Wise MC, Hutnick NA, et al. Chemokine-adjuvanted electroporated DNA vaccine induces substantial protection from simian immunodeficiency virus vaginal challenge. Mucosal Immunol. 2015;9(1):13–23.
   PubMed Web of Science ®Google Scholar
• Panicali D, Davis SW, Weinberg RL, et al. Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin. Proc Natl Acad Sci U S A. 1983;80(17):5364–5368.
   PubMed Web of Science ®Google Scholar
• Smith GL, Mackett M, Moss B. Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen. Nature. 1983;302(5908):490–495.
   PubMed Web of Science ®Google Scholar
• Smith GL, Murphy BR, Moss B. Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters. Proc Natl Acad Sci U S A. 1983;80(23):7155–7159.
   PubMed Web of Science ®Google Scholar
• Moss B. Vaccinia virus: a tool for research and vaccine development. Science. 1991;252(5013):1662–1667.
   PubMed Web of Science ®Google Scholar
• Smith GL, Moss B. Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA. Gene. 1983;25(1):21–28.
   PubMed Web of Science ®Google Scholar
• Kennedy RB, Ovsyannikova I, Poland GA. Smallpox vaccines for biodefense. Vaccine. 2009;27(Suppl 4):D73–79.
   PubMed Web of Science ®Google Scholar
• Meyer H, Sutter G, Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol. 1991;72(Pt 5):1031–1038.
   PubMed Web of Science ®Google Scholar
• Blanchard TJ, Alcami A, Andrea P, et al. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J Gen Virol. 1998;79(Pt 5):1159–1167.
   PubMed Web of Science ®Google Scholar
• Carroll MW, Moss B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology. 1997;238(2):198–211.
   PubMed Web of Science ®Google Scholar
• Stittelaar KJ, Kuiken T, De Swart RL, et al. Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine. 2001;19(27):3700–3709.
   PubMed Web of Science ®Google Scholar
• Wyatt LS, Belyakov IM, Earl PL, et al. Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA. Virology. 2008;372(2):260–272.
   PubMed Web of Science ®Google Scholar
• Burgers WA, Shephard E, Monroe JE, et al. Construction, characterization, and immunogenicity of a multigene modified vaccinia Ankara (MVA) vaccine based on HIV type 1 subtype C. AIDS Res Hum Retroviruses. 2008;24(2):195–206.
   PubMed Web of Science ®Google Scholar
• Cottingham MG, Carroll MW. Recombinant MVA vaccines: dispelling the myths. Vaccine. 2013;31(39):4247–4251.
   PubMed Web of Science ®Google Scholar
• Wyatt LS, Earl PL, Xiao W, et al. Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression resulting from spontaneous mutations and positive selection. J Virol. 2009;83(14):7176–7184.
   PubMed Web of Science ®Google Scholar
• Von Krempelhuber A, Vollmar J, Pokorny R, et al. A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE. Vaccine. 2010;28(5):1209–1216.
   PubMed Web of Science ®Google Scholar
• Yang ZY, Wyatt LS, Kong WP, et al. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol. 2003;77(1):799–803.
   PubMed Web of Science ®Google Scholar
• Ratto-Kim S, Currier JR, Cox JH, et al. Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens. PloS One. 2012;7(9):e45840.
   PubMed Web of Science ®Google Scholar
• Manrique M, Kozlowski PA, Cobo-Molinos A, et al. Long-term control of simian immunodeficiency virus mac251 viremia to undetectable levels in half of infected female rhesus macaques nasally vaccinated with simian immunodeficiency virus DNA/recombinant modified vaccinia virus Ankara. J Immunology. 2011;186(6):3581–3593.
   PubMed Web of Science ®Google Scholar
• Manrique M, Kozlowski PA, Cobo-Molinos A, et al. Resistance to infection, early and persistent suppression of simian immunodeficiency virus SIVmac251 viremia, and significant reduction of tissue viral burden after mucosal vaccination in female rhesus macaques. J Virol. 2014;88(1):212–224.
   PubMed Web of Science ®Google Scholar
• Vogel TU, Reynolds MR, Fuller DH, et al. Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239. J Virol. 2003;77(24):13348–13360.
   PubMed Web of Science ®Google Scholar
• Jm Ar S, Campbell D, Xu Y, et al. DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime. AIDS Res Hum Retroviruses. 2004;20(12):1335–1347.
   PubMed Web of Science ®Google Scholar
• Jm Ar S, McClure HM, Patel M, et al. Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques. AIDS Res Hum Retroviruses. 2004;20(6):654–665.
   PubMed Web of Science ®Google Scholar
• Wyatt LS, Earl PL, Liu JY, et al. Multiprotein HIV type 1 clade B DNA and MVA vaccines: construction, expression, and immunogenicity in rodents of the MVA component. AIDS Res Hum Retroviruses. 2004;20(6):645–653.
   PubMed Web of Science ®Google Scholar
• Lai L, Kwa SF, Kozlowski PA, et al. SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses. Vaccine. 2012;30(9):1737–1745.
   PubMed Web of Science ®Google Scholar
• Kwa S, Lai L, Gangadhara S, et al. CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challenge. J Virol. 2014;88(17):9579–9589.
   PubMed Web of Science ®Google Scholar
• Amara RR, Villinger F, Staprans SI, et al. Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines. J Virol. 2002;76(15):7625–7631.
   PubMed Web of Science ®Google Scholar
• Robinson HL, Sharma S, Zhao J, et al. Immunogenicity in macaques of the clinical product for a clade B DNA/MVA HIV vaccine: elicitation of IFN-gamma, IL-2, and TNF-alpha coproducing CD4 and CD8 T cells. AIDS Res Hum Retroviruses. 2007;23(12):1555–1562.
   PubMed Web of Science ®Google Scholar
• Lai L, Kwa S, Kozlowski PA, et al. Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine. J Infect Dis. 2011;204(1):164–173.
   PubMed Web of Science ®Google Scholar
• Kannanganant S, Gangadhara S, Lai L, et al. Local control of repeated-dose rectal challenges in DNA/MVA-vaccinated macaques protected against a first series of simian immunodeficiency virus challenges. J Virol. 2014;88(10):5864–5869.
   PubMed Web of Science ®Google Scholar
• Amara RR, Smith JM, Staprans SI, et al. Critical role for ENV as well as gag-pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. J Virol. 2002;76(12):6138–6146.
   PubMed Web of Science ®Google Scholar
• Robinson HL, Montefiori DC, Villinger F, et al. Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine. Virology. 2006;352(2):285–294.
   PubMed Web of Science ®Google Scholar
• Lai L, Vodros D, Kozlowski PA, et al. GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine. Virology. 2007;369(1):153–167.
   PubMed Web of Science ®Google Scholar
• Bertley FM, Kozlowski PA, Wang SW, et al. Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates. J Immunology. 2004;172(6):3745–3757.
   PubMed Web of Science ®Google Scholar
• Wang SW, Bertley FM, Kozlowski PA, et al. An SHIV DNA/MVA rectal vaccination in macaques provides systemic and mucosal virus-specific responses and protection against AIDS. AIDS Res Hum Retroviruses. 2004;20(8):846–859.
   PubMed Web of Science ®Google Scholar
• Kannanganat S, Nigam P, Velu V, et al. Preexisting vaccinia virus immunity decreases SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA/MVA vaccine. J Immunology. 2010;185(12):7262–7273.
   PubMed Web of Science ®Google Scholar
• Allen TM, Jing P, Calore B, et al. Effects of cytotoxic T lymphocytes (CTL) directed against a single simian immunodeficiency virus (SIV) Gag CTL epitope on the course of SIVmac239 infection. J Virol. 2002;76(20):10507–10511.
   PubMed Web of Science ®Google Scholar
• Makitalo B, Lundholm P, Hinkula J, et al. Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen. J Gen Virol. 2004;85(Pt 8):2407–2419.
   PubMed Web of Science ®Google Scholar
• Kwa S, Sadagopal S, Shen X, et al. CD40L-adjuvanted DNA/modified vaccinia virus ankara simian immunodeficiency virus (SIV) vaccine enhances protection against neutralization-resistant mucosal SIV infection. J Virol. 2015;89(8):4690–4695.
   PubMed Web of Science ®Google Scholar
• Ellenberger D, Otten RA, Li B, et al. HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges. Virology. 2006;352(1):216–225.
   PubMed Web of Science ®Google Scholar
• Ellenberger D, Wyatt L, Li B, et al. Comparative immunogenicity in rhesus monkeys of multi-protein HIV-1 (CRF02_AG) DNA/MVA vaccines expressing mature and immature VLPs. Virology. 2005;340(1):21–32.
   PubMed Web of Science ®Google Scholar
• Chamcha V, Kannanganat S, Gangadhara S, et al. Strong, but age-dependent, protection elicited by a deoxyribonucleic acid/modified vaccinia ankara simian immunodeficiency virus vaccine. Open Forum Infect Dis. 2016;3(1):ofw034.
   PubMed Web of Science ®Google Scholar
• Shibata R, Igarashi T, Haigwood N, et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med. 1999;5(2):204–210.
   PubMed Web of Science ®Google Scholar
• Shingai M, Donau OK, Plishka RJ, et al. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J Exp Med. 2014;211(10):2061–2074.
   PubMed Web of Science ®Google Scholar
• Huber M, Trkola A. Humoral immunity to HIV-1: neutralization and beyond. J Intern Med. 2007;262(1):5–25.
   PubMed Web of Science ®Google Scholar
• Robinson HL. Non-neutralizing antibodies in prevention of HIV infection. Expert Opin Biol Ther. 2013;13(2):197–207.
   PubMed Web of Science ®Google Scholar
• Florese RH, Demberg T, Xiao P, et al. Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. J Immunology. 2009;182(6):3718–3727.
   PubMed Web of Science ®Google Scholar
• Alpert MD, Harvey JD, Lauer WA, et al. ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge. PLoS Pathog. 2012;8(8):e1002890.
   PubMed Web of Science ®Google Scholar
• Pegu P, Vaccari M, Gordon S, et al. Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial. J Virol. 2013;87(3):1708–1719.
   PubMed Web of Science ®Google Scholar
• Xiao P, Zhao J, Patterson LJ, et al. Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J Virol. 2010;84(14):7161–7173.
   PubMed Web of Science ®Google Scholar
• Burton DR, Hessell AJ, Keele BF, et al. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci U S A. 2011;108(27):11181–11186.
   PubMed Web of Science ®Google Scholar
• Burton SL, Kilgore KM, Smith SA, et al. Breakthrough of SIV strain smE660 challenge in SIV strain mac239-vaccinated rhesus macaques despite potent autologous neutralizing antibody responses. Proc Natl Acad Sci U S A. 2015;112(34):10780–10785.
   PubMed Web of Science ®Google Scholar
• Lewis GK, DeVico AL, Gallo RC. Antibody persistence and T-cell balance: two key factors confronting HIV vaccine development. Proc Natl Acad Sci U S A. 2014;111(44):15614–15621.
   PubMed Web of Science ®Google Scholar
• Fouts TR, Bagley K, Prado IJ, et al. Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection. Proc Natl Acad Sci U S A. 2015;112(9):E992–999.
   PubMed Web of Science ®Google Scholar
• Gordon SN, Doster MN, Kines RC, et al. Antibody to the gp120 V1/V2 loops and CD4+ and CD8+ T cell responses in protection from SIVmac251 vaginal acquisition and persistent viremia. J Immunology. 2014;193(12):6172–6183.
   PubMed Web of Science ®Google Scholar
• Barouch DH, Alter G, Broge T, et al. HIV-1 vaccines. Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. Science. 2015;349(6245):320–324.
   PubMed Web of Science ®Google Scholar
• Iyer SS, Gangadhara S, Victor B, et al. Codelivery of envelope protein in alum with MVA vaccine induces CXCR3-biased CXCR5+ and CXCR5- CD4 T cell responses in rhesus macaques. J Immunology. 2015.
   Web of Science ®Google Scholar
• Sanders RW, Van Gils MJ, Derking R, et al. HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science. 2015;349(6244):aac4223.
   PubMed Web of Science ®Google Scholar
• Garcia-Arriaza J, Najera JL, Gomez CE, et al. A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses. PloS One. 2011;6(8):e24244.
   PubMed Web of Science ®Google Scholar
• Falivene J, Del Medico Zajac MP, Pascutti MF, et al. Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein. PloS One. 2012;7(2):e32220.
   PubMed Web of Science ®Google Scholar
• Perdiguero B, Gomez CE, Najera JL, et al. Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens. PloS One. 2012;7(10):e48524.
   PubMed Web of Science ®Google Scholar
• Garcia-Arriaza J, Najera JL, Gomez CE, et al. Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions. PloS One. 2010;5(8):e12395.
   PubMed Web of Science ®Google Scholar
• Garcia-Arriaza J, Gomez CE, Sorzano CO, et al. Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens. J Virol. 2014;88(6):3392–3410.
   PubMed Web of Science ®Google Scholar
• Rehm KE, Roper RL. Deletion of the A35 gene from modified vaccinia virus ankara increases immunogenicity and isotype switching. Vaccine. 2011;29(17):3276–3283.
   PubMed Web of Science ®Google Scholar
• Garber DA, O’Mara LA, Gangadhara S, et al. Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques. J Virol. 2012;86(23):12605–12615.
   PubMed Web of Science ®Google Scholar
• Goepfert PA, Elizaga ML, Seaton K, et al. Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis. 2014;210(1):99–110.
   PubMed Web of Science ®Google Scholar
• Mehendale S, Thakar M, Sahay S, et al. Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised trial in HIV-uninfected Indian volunteers. PloS One. 2013;8(2):e55831.
   PubMed Web of Science ®Google Scholar
• Ramanathan VD, Kumar M, Mahalingam J, et al. A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers. AIDS Res Hum Retroviruses. 2009;25(11):1107–1116.
   PubMed Web of Science ®Google Scholar
• Karasavvas N, Billings E, Rao M, et al. The thai phase III HIV type 1 vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses. 2012;28(11):1444–1457.
   PubMed Web of Science ®Google Scholar
• Goepfert PA, Tomaras GD, Horton H, et al. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. Vaccine. 2007;25(3):510–518.
   PubMed Web of Science ®Google Scholar
• Amanna IJ, Slifka MK. Mechanisms that determine plasma cell lifespan and the duration of humoral immunity. Immunol Rev. 2010;236:125–138.
   PubMed Web of Science ®Google Scholar
• Hayes P, Gilmour J, Von Lieven A. et al. Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adults. Clin Vaccine Immunol. 2013;20(3):397–408.
   PubMed Web of Science ®Google Scholar
• Munseri PJ, Kroidl A, Nilsson C, et al. Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trial. PloS One. 2015;10(4):e0119629.
   PubMed Web of Science ®Google Scholar
• Bakari M, Aboud S, Nilsson C, et al. Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania. Vaccine. 2011;29(46):8417–8428.
   PubMed Web of Science ®Google Scholar
• Joachim A, Nilsson C, Aboud S, et al. Potent functional antibody responses elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy tanzanian adults. PloS One. 2015;10(4):e0118486.
   PubMed Web of Science ®Google Scholar
• Kim JH, Excler JL, Michael NL. Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection. Annu Rev Med. 2015;66:423–437.
   PubMed Web of Science ®Google Scholar
• Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol. 2011;29:621–663.
   PubMed Web of Science ®Google Scholar
• Casazza JP, Brenchley JM, Hill BJ, et al. Autocrine production of beta-chemokines protects CMV-Specific CD4 T cells from HIV infection. PLoS Pathog. 2009;5(10):e1000646.
   PubMed Web of Science ®Google Scholar
• Shinkawa T, Nakamura K, Yamane N, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem. 2003;278(5):3466–3473.
   PubMed Web of Science ®Google Scholar
• Shields RL, Lai J, Keck R, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem. 2002;277(30):26733–26740.
   PubMed Web of Science ®Google Scholar
• Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med. 2005;11(4 Suppl):S45–53.
   PubMed Web of Science ®Google Scholar
• Belyakov IM, Berzofsky JA. Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines. Immunity. 2004;20(3):247–253.
   PubMed Web of Science ®Google Scholar
• Demberg T, Robert-Guroff M. Mucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design. Int Rev Immunol. 2009;28(1–2):20–48.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Hidajat R, Peng B, et al. Comparative evaluation of oral and intranasal priming with replication-competent adenovirus 5 host range mutant (Ad5hr)-simian immunodeficiency virus (SIV) recombinant vaccines on immunogenicity and protective efficacy against SIVmac251. Vaccine. 2007;25(47):8021–8035.
   PubMed Web of Science ®Google Scholar
• Ganguly S, Manicassamy S, Blackwell J, et al. Adenovirus type 5 induces vitamin A-metabolizing enzymes in dendritic cells and enhances priming of gut-homing CD8 T cells. Mucosal Immunol. 2011;4(5):528–538.
   PubMed Web of Science ®Google Scholar